Page 35 - JCTR-11-1

Journal of Clinical and
Translational Research Dexamethasone in critical COVID-19

Table 1. Clinical and laboratory features
Features Patient number (%) Demise
Yes No
n (%) n (%)
Sex Distribution - n (%)
Female 11 (50.0) 5 (45.5) 6 (54.5)
Male 11 (50.0) 4 (36.4) 7 (63.6)
Age
Mean, years (CI) 62.14 (54.6 – 69.7) 67.7 (54.0 – 80.0) 58.8 (48.5 – 69.1)
Distribution - n (%)
<50 5 (22.7) 1 (20.0) 5 (80.0)
50 – 70 10 (45.5) 4 (40.0) 6 (60.0)
≥70 7 (31.8) 4 (57.1) 3 (42.9)
Hospitalization time
Mean, years (CI) 14.4 (10.8 – 18.0) 11.8 (6.2 – 17.3) 16.2 (11.1 – 21.4)
Distribution - n (%)
<10 9 (40.9) 5 (55.6) 4 (44.4)
10 – 20 7 (31.8) 3 (42.9) 4 (57.1)
≥20 6 (27.3) 1 (16.7) 5 (83.3)
BMI
Distribution - n (%)
Low weight <18.5 0 (0.0) 0 (0.0) 0 (0.0)
Normal 18.5 – 25 5 (22.7) 3 (60.0) 2 (40.0)
Overweight 25 – 30 6 (27.3) 3 (50.0) 3 (50.0)
Obesity ≥30 9 (40.9) 3 (33.3) 6 (66.7)
No collection 2 (9.1) 0 (0.0) 2 (100.0)
Creatinine (Reference range: 0.50 – 0.90 mg/mL)
Highly elevated parameter - n (%) 8 (36.6) 7 (87.5) 1 (12.5)
AST (Reference range: Woman <35 U/L; Man <50 U/L)
Highly elevated parameter - n (%) 14 (63.6) 8 (57.1) 6 (42.9)
No collection 2 (9.1) 2 (100.0)
ALT (Reference range: Woman <33 U/L; Man<41 U/L)
Highly elevated parameter - n (%) 13 (59.1) 7 (53.8) 6 (46.2)
No collection 2 (9.1) 2 (100.0)
Ferritin (Reference range: Woman 13 – 150 ng/mL; 20 (90.9) 8 (40.0) 12 (60.0)
Man 30 – 400 ng/mL) - n (%)
No collection 2 (9.1) 1 (50.0) 1 (50.0)
Fibrinogen (Reference range: 200 – 450 mg/dL) - n (%) 16 (72.7) 6 (37.5) 10 (62.5)
No collection 4 (18.2) 1 (25.0) 3 (75.0)
D-dimer (Reference range <500 ng/mL) - n (%) 12 (54.5) 5 (41.7) 7 (58.3)
No collection 6 (27.3) 3 (50.0) 3 (50.0)
Platelets
Distribution - n (%)
<150,000 2 (9.1) 2 (100.0) 0 (0.0)
150,000 – 450,000 19 (86.4) 7 (36.8) 12 (63.2)
>450,000 1 (4.5) 0 (0.0) 1 (100.0)
Glucose
Distribution - n (%)
<70 0 (0.0) 0 (0.0) 0 (0.0)
70 – 99 3 (13.6) 1 (33.3) 2 (66.7)
>99 19 (86.4) 8 (42.1) 11 (57.9)
Hemoglobin
Distribution - n (%) 0 (0.0)
<5.7 0 (0.0) 0 (0.0) 0 (0.0)
5.7 – 6.4 0 (0.0) 0 (0.0) 13 (59.1)
>6.4 22 (100.0) 9 (40.9)
(Cont'd...)

Volume 11 Issue 1 (2025) 29 doi: 10.36922/jctr.24.00036